The Technical Analyst
Apollomics, Inc. [APLM]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Apollomics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.62% $0.403
/ 7 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 36.02 mill |
| EPS: | -2.32 |
| P/E: | -0.170 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 89.50 mill |
| Avg Daily Volume: | 0.183 mill |
| RATING 2024-05-07 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | |||||
|---|---|---|---|---|---|
| 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | ||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.170 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.170 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.365 (-9.31%) $-0.0375 |
| Date: 2024-04-01 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.344 - 0.462 ( +/- 14.66%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.403
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.403
Forecast 2: 16:00 - $0.403
Forecast 3: 16:00 - $0.403
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.403 (-0.62% ) |
| Volume | 0.0443 mill |
| Avg. Vol. | 0.183 mill |
| % of Avg. Vol | 24.27 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APLM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | buy | $0.710 | N/A | Active |
|---|
APLM
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Latest Press Releases
2024-04-25 08:30:00 - Press Release
Apollomics Announces Approval Of Vebreltinib In China As A First-in-class Treatment For Gliomas With Met Fusion Gene
Apollomics' partner in china, avistone, received approval from national medical products administration of china to expand the use of vebreltinib to the treatment of gliomas with ptprz1-met fusion gene
2024-04-10 07:00:00 - Press Release
Apollomics Presents Vebreltinib Data At The 2024 American Association For Cancer Research (aacr) Annual Meeting
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying met-driver alterations, and effective for overcoming met-amplification dependent resistance to egfr therapies in egfr-positive non-small cell lung cancer preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying met-driver alterations, and effective for overcoming met-amplification dependent resistance to egfr therapies in egfr-positive non-small cell lung cancer
2024-03-28 07:00:00 - Press Release
Apollomics Highlights Clinical Progress And Reports Full Year 2023 Financial Results
Foster city, calif., march 28, 2024 (globe newswire) -- apollomics inc. (nasdaq: aplm) (“apollomics” or the “company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended december 31, 2023, and highlighted progress of its pipeline.
2024-03-04 07:00:00 - Press Release
Apollomics Appoints Matthew Plunkett, Ph.d. As Chief Financial Officer
Foster city, calif., march 04, 2024 (globe newswire) -- apollomics inc. (“apollomics” or the “company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that matthew plunkett, ph.d., has been appointed as chief financial officer of apollomics.
2024-02-07 07:00:00 - Press Release
Apollomics To Present At The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Foster city, calif., feb. 07, 2024 (globe newswire) -- apollomics inc. (“apollomics” or the “company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that guo-liang yu, ph.d., chairman and chief executive officer of apollomics, and sanjeev redkar, ph.d., president of apollomics, will present virtually at the oppenheimer 34th annual healthcare life sciences conference on wednesday, february 14, 2024 at 10:40 a.m. et.
Latest News
2024-02-07 07:00:00 - GlobeNewsWire
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 10:40 a.m. ET.
2024-01-02 16:30:00 - GlobeNewsWire
Apollomics to Present at the 2024 Biotech Showcase
FOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024 Biotech Showcase on Monday, January 8, 2024 at 10:30 a.m. PT at the Hilton San Francisco Union Square in San Francisco, Calif.
2023-11-29 07:30:00 - GlobeNewsWire
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that Guo-Liang Yu, Ph.D., Co-Founder and Chief Executive Officer of Apollomics and Sanjeev Redkar, Ph.D., Co-Founder and President, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:30 a.m. ET.
2023-10-27 08:03:36 - InvestorPlace
Why Is Apollomics (APLM) Stock Up 113% Today?
Apollomics (NASDAQ: APLM ) stock is rising higher on Friday as the shares bounce back on recent study results. Those study results cover the “efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion.
2023-09-06 07:00:00 - GlobeNewsWire
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that Sanjeev Redkar, Ph.D., Co-Founder, Executive Director and President, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023 at 10:30 a.m. ET at the Lotte New York Palace in New York, NY.
2023-08-29 06:21:19 - Seeking Alpha
Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline
Apollomics is a small company with a pipeline of c-Met targeting small molecule TKIs for various cancers. Their lead candidate, Vebreltinib, is in phase 2 trials for NSCLC, GBM, and other solid tumors. They also have a second asset, APL-106, which is a specific E-Selectin antagonist being explored as a therapeutic target in certain types of cancer metastasis.
2023-06-07 20:56:18 - InvestorPlace
The 7 Most Promising Penny Stocks to Buy in June
Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.
2023-06-02 11:20:39 - The Motley Fool
Why Shares of Apollomics Are Up Friday
Apollomics focuses on therapies for hard-to-treat cancers. The company has nine therapies, with six in clinical trials.
2023-04-26 07:45:45 - Benzinga
Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.